WASHINGTON President Donald Trump's pick for U.S. drug czar withdrew on Tuesday after it become public that he spearheaded a bill that undercut the government's power to crack down on opioid makers that were flooding the market with the addictive painkillers. | Video
- J&J wins reversal of $72 million verdict over talc cancer risks
- New cancer drugs help J&J top profit estimates
- China confirms bird flu outbreak at poultry farms in central province
- UnitedHealth sees growth in 2018, a year of changes by Trump
- Transenterix won't compete head-on with Intuitive Surgical: CEO
(Reuters Health) - Nonalcoholic fatty liver disease and its more aggressive form, nonalcoholic steatohepatitis, have become the fastest-growing reasons for liver transplants in young Americans, according to a recent study.
Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing environment.
TOKYO Haruta Saito, a young Japanese amputee who dreams of becoming a Paralympian, remembers strapping on a prosthetic "running blade" for the first time.
WASHINGTON U.S. President Donald Trump said on Monday he would review a report that his nominee for drug czar championed a law that weakened the government's ability to fight the nation's opioid epidemic, and said he could consider jettisoning the pick.